Open Access

Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy

MIYATA TAKASHI 1
TOMITA YASUTO 1
SAN-NOMIYA YUTA 1
NAGAYAMA TAIGO 1
KIN RYOSUKE 1
NISHIKI HISASHI 1
HASHIMOTO AKIFUMI 1
FUJII YORITAKA 1
MIURA SEIKO 1
KAIDA DAISUKE 1
NAKAMURA NAOHIKO 1
MIYASHITA TOMOHARU 1
FUJITA HIDETO 1
UEDA NOBUHIKO 1
  &  
TAKAMURA HIROYUKI 1

Department of General and Digestive Surgery, Kanazawa Medical University Hospital, Ishikawa, Japan

Cancer Diagnosis & Prognosis Jan-Feb; 2(1): 15-24 DOI: 10.21873/cdp.10071
Received 28 August 2021 | Revised 21 July 2024 | Accepted 18 October 2021
Corresponding author
Takashi Miyata, MD, Department of General and Digestive Surgery, Kanazawa Medical University Hospital, Ishikawa, Japan. Tel: +81 762862211, Fax: +81 762864626 ryutami5383917@gmail.com

Abstract

Background/Aim: Following oxaliplatin-based chemotherapy, approximately half of all colorectal cancer patients develop sinusoidal obstruction syndrome (SOS). SOS can be monitored by measuring splenic volume; however, obtaining this measurement is not a simple process. In this study, we evaluated changes in hyaluronic acid (HA) concentrations as a simpler marker of SOS. Patients and Methods: We measured splenic volume and laboratory data, including hyaluronic acid concentration, liver enzymes, and platelet counts, in 34 patients with colorectal cancer who underwent radical resection and who received capecitabine plus oxaliplatin (CapeOx) chemotherapy. Results: A strong correlation was identified between ≥30% increase in splenic volume and significantly elevated HA concentrations. Affected patients also had persistent thrombocytopenia and liver dysfunction compared to patients without elevated HA concentration. Conclusion: HA concentration may predict SOS in patients who receive CapeOx adjuvant chemotherapy.
Keywords: Hyaluronic acid, splenic volume, oxaliplatin, sinusoidal obstruction syndrome

Colorectal cancer (CRC) is the third most common cancer and has the second highest cancer-related mortality rate (1); postoperative adjuvant chemotherapy is the standard treatment in stage III CRC (2). Oxaliplatin-based chemotherapy is a key regimen for CRC, and oxaliplatin is included in the capecitabine plus oxaliplatin (CapeOX) regimen (3). However, oxaliplatin may induce hepatic sinusoidal obstruction syndrome (SOS) (4).

Approximately 30% of patients with CRC develop metachronous liver metastases, and hepatectomy is the only potentially curative treatment (5). Moreover, approximately half of patients treated with oxaliplatin develop SOS, which leads to significant postoperative adverse effects, especially after major liver resection (6-8). Early SOS assessment is necessary; however, an effective strategy remains to be determined.

Increasing splenic volume (SV) may predict the risk of SOS (9); however, measuring SV is complicated. SOS may result from drug-induced injury to liver sinusoidal endothelial cells (LSEC), and hyaluronic acid (HA), present in LSEC, was a marker for SOS in a rat experimental model (10). Therefore, we evaluated HA as a prognostic marker for early SOS assessment. We measured HA before and after CapeOX adjuvant chemotherapy in patients with stage III CRC after curative surgical resection, and investigated the relationships and changes in treatment progression between SV, platelets, and liver dysfunction, as indicators of SOS.

Patients and Methods

Patient selection. We identified 34 patients with stage III CRC in our hospital database who underwent radical resection between January 2017 and June 2020, and who received CapeOX adjuvant chemotherapy. We excluded patients with <6 oxaliplatin-based adjuvant chemotherapy cycles; lacking blood HA results or computed tomography (CT) imaging; metastatic disease during chemotherapy; additional chemotherapy agents or prior splenectomy; known cirrhosis; chronic viral hepatitis; or prior liver surgery. This study was approved by the Institutional Review Board of the Kanazawa Medical University Hospital.

Clinical data. We retrospectively collected the patients’ sex, age, body mass index, characteristics of the primary cancer and surgical procedure, postoperative course, number of chemotherapy cycles, pathological factors, SV, and laboratory data, namely hepatobiliary system enzymes, platelets, and HA concentration. SV and laboratory data were measured four times: i: before, ii: immediately after, iii: 6 months after, and iv: 1 year after adjuvant CapeOX therapy. Changes in SV were determined by comparing the value at each time point with the value before treatment. In this study, we defined splenomegaly as a 30% increase in SV when comparing ii to i. The correlations between HA change and SV change ratio, platelets, and liver enzymes were investigated. The patients were divided into two groups: Group A: ≥30% increase in SV at ii compared with i; Group B: the remaining patients. The outcomes for all patients and for each group were investigated. Thrombocytopenia was defined as <150,000 platelets/mm3. SV was calculated using multi-detector row CT (Hitachi Medical Corporation, Saitama, Japan) and by loading the CT images onto the calculator software, Ziostation 2® (Zaiosoft, Tokyo, Japan). Additionally, we performed hepatectomy for recurrent liver metastasis in two patients in each group >6 months after CapeOX, and pathologically examined a normal site in the hepatectomy specimen and investigated the relationship between the pathological findings and preoperative HA level.

Statistical analysis. Values were expressed as means±standard deviations (SD). Statistical analyses were performed using the two-sided Student’s t-test and the Mann–Whitney U-test for continuous data or Fisher’s exact test. All statistical analyses were performed using SPSS 10.0 (SPSS, Chicago, IL, USA). Significance was defined as p<0.05.

Results

Thirty-four patients were included; Group A (splenomegaly) comprised 17 patients, and Group B (no splenomegaly) comprised 17 patients. There were no differences in the groups’ clinical characteristics (Table I).

Analyzing all patients, adjuvant CapeOX resulted in a significant increase in HA at ii vs. i (p<0.001), and at iii (p=0.020). Platelet counts decreased significantly at ii (p<0.001), which persisted at iii (p=0.002) and iv (p=0.011). Aspartate aminotransferase (AST) (p<0.001) and alanine aminotransferase (ALT) (p=0.007) levels increased significantly at ii compared to i; AST levels remained significantly increased at iii (p=0.001) (Figure 1A). Changes in SV for all patients are presented in Figure 2. The mean SV at ii increased significantly to 137.3% compared to i (p=0.032). Resolution of splenomegaly was confirmed (mean SV: 121%) at iii, and SV returned to almost the initial level (mean: 110.1%) at iv (Table II). The percentage change in SV from i to ii was related to the percentage change in HA from i to ii (Figure 3).

Changes in laboratory data within in the groups are shown in Figure 1B and C. In Group A, HA levels increased significantly at ii (p<0.001) and iii (p=0.013) compared with i. Platelet counts decreased significantly at ii (p<0.001), which persisted at iii (p=0.009) and iv (p=0.018). AST (p<0.001), ALT (p=0.007), and γ-glutamyl transpeptidase (γGT) (p=0.029) levels increased significantly at ii compared to i. AST (p=0.002) and γGT (p=0.021) levels remained significantly changed at iii (Figure 1B). The mean SV at ii and iii increased significantly to 163.4% (p=0.009) and 136.5% (p=0.061), respectively, compared to i, and improved to 119.4% at iv (Table II). However, SV in three patients (21%) remained ≥30% even at iv (Figure 2). In contrast, in Group B, HA levels increased significantly at ii (p=0.014), then improved at iii and iv. Platelet counts decreased significantly at ii (p=0.008), and improved at iii and iv. AST levels increased significantly (p=0.004) at ii compared with i; however, values improved, and did not change significantly at iii (Figure 1C). Mean SV did not increase at any time after chemotherapy, compared to i (Table II). Thrombocytopenia (cut-off: <15 × 104/μl) during CapeOX treatment differed significantly in all 17 cases (100%) in Group A and in 4 cases (28.6%) in Group B (p<0.001).

Further examination of the HA results revealed that the cut-off value at time ii according to the receiver operating characteristic curve between Groups A and B was 138 ng/ml, with an area under the curve of 0.830 (Figure 4). HA in all patients in Group B was <138 ng/ml at ii, with a slightly low specificity of 64.7%, and sensitivity of 100%.

Of the 34 patients, 2 patients experienced liver recurrence >6 months after finishing chemotherapy. One patient in Group A underwent hepatectomy 4 months after CapeOX therapy, and another patient in Group B underwent hepatectomy 6 months after CapeOX. In the Group A patient, HA was 246 ng/ml at ii, and liver SOS was revealed pathologically (Figure 5A). However, in the Group B patient, HA was 94 ng/ml, with a normal liver (Figure 5B).

Discussion

The novel findings in this study were that 50% of patients who received CapeOX as adjuvant chemotherapy for stage III CRC developed splenomegaly immediately after chemotherapy, and splenomegaly was associated with a significant increase in HA. Moreover, patients with significantly elevated HA had higher rates of remarkable thrombocytopenia and liver dysfunction during and even after CapeOX administration, indicative of SOS.

Although Rubbia-Brandt et al. (4) reported an association between oxaliplatin-based chemotherapy and SOS in patients with liver metastatic CRC, clinically useful prediction methods for this side-effect are poorly documented. Recent studies have addressed the efficacy of increasing SV to predict SOS in CRC patients (9,11). However, monitoring SV cannot be performed without CT, and CT imaging usually has monthly intervals. Recently, patients receiving CapeOX after CRC surgery (3) have developed SOS, which can be detrimental to the treatment of recurrent liver metastasis (6-8).

Several studies have reported that initial pathophysiological changes in SOS may result from drug-induced injury to LSEC (10,12,13), and HA is metabolized almost exclusively by LSEC (14). Serum HA is elevated after bone marrow transplantation in patients with moderate or severe SOS (15). Moreover, SOS in a monocrotaline-induced rat model of SOS showed that HA was significantly increased in severe SOS and significantly decreased in mild SOS (10,13), supporting HA as a predictive biomarker of SOS.

We found a strong correlation between patients with significantly elevated HA and those with a ≥30% increase in SV after CapeOX. In these patients, there was also marked and persistent thrombocytopenia, persistent liver dysfunction, and a persistent increase in HA compared to patients without increased HA during and after chemotherapy. There is a strong correlation between splenomegaly and thrombocytopenia or increased liver function caused by SOS in patients receiving oxaliplatin-based-chemotherapy (4,6,8,9); however, our results suggest that SOS evaluation is possible using HA instead of SV. Oxaliplatin-induced SOS may continue for more than a year after chemotherapy (9,11), consistent with our results.

The results of this study are important because they support the hypothesis that systemic indicators of drug-induced injury to LSEC may serve as simple biomarkers of SOS in CRC patients receiving oxaliplatin-based chemotherapy. However, in order to prove the specificity of measured HA levels for oxaliplatin-induced injury of liver sinusoidal endothelial cells, further studies are required that take into account the tumor as a source of systemic HA.

As a limitation, we evaluated the records of only 34 patients who received CapeOX chemotherapy for stage III CRC. Additionally, this was a retrospective and non-randomized study. Third, because liver biopsy was not performed, we chose increased HA as a possible biomarker of SOS. The correlation between liver dysfunction induced by chemotherapy and the development of SOS in pathological examination remains unclear. However, this study does not require CT examinations, which are necessary for measuring spleen volume, and can be done only by collecting blood, so it has the advantage of being easily tackled in future prospective studies.

In conclusion, splenomegaly, prominent thrombocytopenia, and liver dysfunction were confirmed after oxaliplatin-based adjuvant chemotherapy, possibly owing to SOS. We believe that increased HA after oxaliplatin-based chemotherapy is strongly associated with these outcomes and may predict SOS.

Conflicts of Interest

The Authors declare they have no financial or other conflicts of interest.

Authors’ Contributions

Takashi M and HT designed the study. TM, HT, YS, TN, RK, HN, AH, YF, SM, DK, YT, NN, TM, HF, and NU performed data acquisition, analysis, and interpretation. Takashi M prepared the manuscript. TM revised the paper critically. All Authors read and approved the final manuscript.

Acknowledgements

We thank Jane Charbonneau, DVM, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

References

1 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA & Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6) 394 - 424 2018. PMID: 30207593. DOI: 10.3322/caac.21492
2 Sargent DJ Wieand HS Haller DG Gray R Benedetti JK Buyse M Labianca R Seitz JF O'Callaghan CJ Francini G Grothey A O'Connell M Catalano PJ Blanke CD Kerr D Green E Wolmark N Andre T Goldberg RM & De Gramont A Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 23(34) 8664 - 8670 2005. PMID: 16260700. DOI: 10.1200/JCO.2005.01.6071
3 André T de Gramont A Vernerey D Chibaudel B Bonnetain F Tijeras-Raballand A Scriva A Hickish T Tabernero J Van Laethem JL Banzi M Maartense E Shmueli E Carlsson GU Scheithauer W Papamichael D Möehler M Landolfi S Demetter P Colote S Tournigand C Louvet C Duval A Fléjou JF & de Gramont A Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 33(35) 4176 - 4187 2015. PMID: 26527776. DOI: 10.1200/JCO.2015.63.4238
4 Rubbia-Brandt L Audard V Sartoretti P Roth AD Brezault C Le Charpentier M Dousset B Morel P Soubrane O Chaussade S Mentha G & Terris B Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 15(3) 460 - 466 2004. PMID: 14998849. DOI: 10.1093/annonc/mdh095
5 Manfredi S Lepage C Hatem C Coatmeur O Faivre J & Bouvier AM Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 244(2) 254 - 259 2006. PMID: 16858188. DOI: 10.1097/01.sla.0000217629.94941.cf
6 Nakano H Oussoultzoglou E Rosso E Casnedi S Chenard-Neu MP Dufour P Bachellier P & Jaeck D Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 247(1) 118 - 124 2008. PMID: 18156931. DOI: 10.1097/SLA.0b013e31815774de
7 Tamandl D Klinger M Eipeldauer S Herberger B Kaczirek K Gruenberger B & Gruenberger T Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 18(2) 421 - 430 2011. PMID: 20844968. DOI: 10.1245/s10434-010-1317-4
8 Nordlinger B Sorbye H Glimelius B Poston GJ Schlag PM Rougier P Bechstein WO Primrose JN Walpole ET Finch-Jones M Jaeck D Mirza D Parks RW Collette L Praet M Bethe U Van Cutsem E Scheithauer W Gruenberger T EORTC Gastro-Intestinal Tract Cancer Group Cancer Research UK Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) Australasian Gastro-Intestinal Trials Group (AGITG) & Fédération Francophone de Cancérologie Digestive (FFCD) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 371(9617) 1007 - 1016 2008. PMID: 18358928. DOI: 10.1016/S0140-6736(08)60455-9
9 Miyata T Takamura H Kin R Nishiki H Hashimoto A Fujii Y Miura S Fujita J Kaida D Tomita Y Nakamura N Fujita H Kinami S Ueda N & Kosaka T Spleen volume as a predictive biomarker for thrombocytopenia and liver dysfunction after oxaliplatin-based chemotherapy. Anticancer Res. 40(6) 3361 - 3370 2020. PMID: 32487632. DOI: 10.21873/anticanres.14319
10 Miyata T Tajima H Hirata M Nakanuma SI Makino I Hayashi H Oyama K Miyashita T Takamura H Ninomiya I Fushida S Iseki S Harada SI Wakayama T & Ohta T Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space. J Gastroenterol Hepatol. 33(4) 950 - 957 2018. PMID: 28960464. DOI: 10.1111/jgh.14004
11 Iwai T Yamada T Koizumi M Shinji S Yokoyama Y Takahashi G Takeda K Hara K Ohta K & Uchida E Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. J Surg Oncol. 116(7) 947 - 953 2017. PMID: 28876454. DOI: 10.1002/jso.24756
12 DeLeve LD DeLeve LD & GarciaTsao G Vascular liver disease and the liver sinusoidal endothelial cell. In: Vascular Liver Disease. New York, Springer. pp 25 2011.
13 Hirata M Tajima H Miyashita T Miyata T Nakanuma S Makino I Hayashi H Oyama K Takamura H Ninomiya I Fushida S Nakata H Iseki S Harada S Wakayama T & Ohta T Extravasated platelet aggregation in the livers of rats with drug induced hepatic sinusoidal obstruction syndrome. Mol Med Rep. 15(5) 3147 - 3152 2017. PMID: 28358421. DOI: 10.3892/mmr.2017.6407
14 Yao L Yao ZM & Yu T Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gastroenterol. 7(6) 872 - 875 2001. PMID: 11854920. DOI: 10.3748/wjg.v7.i6.872
15 Fried MW Duncan A Soroka S Connaghan DG Farrand A Peter J Strauss RM Boyer TD & McDonald GB Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 27(6) 635 - 639 2001. PMID: 11319594. DOI: 10.1038/sj.bmt.1702821